End-of-day quote
Other stock markets
|
||
- USD | - |
04-23 | Silo Pharma, Inc. Announces Positive Results for Intranasal PTSD Treatment | CI |
04-10 | Silo Pharma Says It Exercised Option to License Alzheimer's Therapeutic From Columbia University | MT |
Sales 2024 * | 72K 98.28K | Sales 2025 * | 72K 98.28K | Capitalization | 5.15M 7.03M |
---|---|---|---|---|---|
Net income 2024 * | -4M -5.46M | Net income 2025 * | -8M -10.92M | EV / Sales 2024 * | 71.5 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 71.5 x |
P/E ratio 2024 * |
-3.23
x | P/E ratio 2025 * |
-2.59
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.01% |
Managers | Title | Age | Since |
---|---|---|---|
Eric Weisblum
CEO | Chief Executive Officer | 54 | 10-07-12 |
Daniel Ryweck
DFI | Director of Finance/CFO | 59 | 22-09-26 |
James Kuo
CTO | Chief Tech/Sci/R&D Officer | 58 | 22-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Eric Weisblum
CEO | Chief Executive Officer | 54 | 10-07-12 |
Wayne Linsley
BRD | Director/Board Member | 67 | 20-01-15 |
Kevin Muñoz
BRD | Director/Board Member | 46 | 20-09-30 |
1st Jan change | Capi. | |
---|---|---|
-1.48% | 89.37B | |
+2.76% | 40.65B | |
-12.32% | 32.81B | |
+52.41% | 25B | |
-17.39% | 15.29B | |
-42.45% | 11.61B | |
-10.48% | 11.49B | |
+6.14% | 8.98B | |
-7.72% | 8.23B |
- Stock Market
- Equities
- SILO Stock
- GDSW Stock